Scott Rowland’s Post

How to Use Drug Sales Data to Refine Your Channel Strategy and Improve Your Portfolio Management

How to Use Drug Sales Data to Refine Your Channel Strategy and Improve Your Portfolio Management

Fierce Pharma does some excellent reporting and they did a nice job summarizing the lawsuit between AMGN and Karyopharm Therapeutics Inc. in 2019, but the missed the main point: The sales reps that were recruited from AMGN only knew Kyprolis. That is a Medicare Part B drug. XPOVIO® (selinexor) HCP is an oral oncolytic or small molecule - KPTI SHOULD have hired reps from Celgene Pharma but they did not want to deal with the nausea profile of selinexor given the too-high dosing. I did not work for KPTI in 2019 - I was on paternity leave when this story broke in May. However, it is events like these that made me want to buy shares of KPTI starting around 69 cents a share to help fix it! Help is on the way, my Boston Biotech Advisors, LLC friends! We will get it right this time. I promise! God Bless America! 🇺🇸 ~Jeff Conroy Global HC Analytics LLC We offer best in class multiple myeloma CI, forecasting, and data analytics. And KPTI needs new leadership and a line-by-line budget item review based on my experience there. 👍 ☘️ I own a significant stake in KPTI and will be releasing my expectations here and on Twitter X soon. Not demands: Expectations. 😉 https://lnkd.in/esVwx3K7

Semaglutide's Sales Reached an Astonishing $13 Billion in the First Half of 2024, Eyeing the Title of "Drug King" In the first half of this year, GLP-1 sales totaled 99.7 billion Danish krone (USD 14.6 billion), compared to 76.8 billion Danish krone (USD 11.2 billion) in the first half of 2023. Among these, the company's star product, semaglutide, generated approximately USD 12.9 billion in sales, accounting for two-thirds of Novo Nordisk's total revenue for the period. As a result, semaglutide has the potential to secure the title of "Global Drug King" for 2024. In 2022, the title was held by AbbVie’s Humira, and in 2023, Merck’s Keytruda (commonly referred to as "K drug") took the top spot with annual sales of USD 25 billion. In the first half of 2024, Keytruda's sales were USD 14.2 billion, marking a 21% increase year-over-year. With Novo Nordisk ramping up production and semaglutide scaling up, its growth rate is also competitive against Keytruda. CEO Lars Fruergaard Jørgensen stated in a prepared statement, “We are pleased with the sales growth in the first half of 2024, which allows us to raise our full-year performance expectations. The growth is driven by increased demand for GLP-1-based diabetes and obesity treatments, and we will continue to benefit more patients through innovative therapies.” Transco provides an opportunity to purchase semaglutide and tirzepatide APIs directly from China. We collaborate with over 12 factories in China, and we can meet your API requirements based on your needs (for example DMF, NDC, original product name, import and customs clearance, FDA audit). Additionally, we can assist you with all the processes from the factory in China to your office, helping you receive the goods smoothly.

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised.   Group sales were up by 5%1 at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8%. Group sales growth accelerated to 9% (7% in CHF) in the second quarter as the decline in COVID-19-related sales no longer had an impact on overall sales. Pharmaceuticals Division sales rose by 5% in the first half; strong growth of 8% in the base business2 excluding COVID-19 effect was driven by continued high demand for our newer medicines to treat severe diseases; eye medicine Vabysmo was again the major growth driver. Diagnostics Division sales rose by 5%, while growth in the base business, which excludes the impact of COVID-19 sales, was 9% due to higher demand for immunodiagnostic products. Core operating profit increased by 11% (4% in CHF), core earnings per share grew by 9% (1% in CHF) and IFRS net income was down by 4%. Outlook for 2024 earnings raised.   Roche CEO Thomas Schinecker: “Our strong sales growth in the first half of 2024 reflects the high demand for our innovative medicines and diagnostics. In the second quarter, we saw an acceleration of our growth momentum as Group sales were no longer impacted by the decline in COVID-19 sales, resulting in very strong sales growth for the Group. Based on our strong half-year results, we are raising our earnings outlook for the full year. We also received a number of important regulatory approvals in the last three months, including EU approval for Alecensa for a form of early-stage lung cancer, as well as for the subcutaneous injection of Ocrevus, which provides an additional treatment option for multiple sclerosis. I am particularly pleased about the US approval for the ready-to-use prefilled syringe of our eye medicine Vabysmo, which continues to be our main growth driver. In diagnostics, our new Accu-Chek SmartGuide solution for continuous blood glucose monitoring uses artificial intelligence to provide reliable blood glucose level forecasts for several hours.” #RocheDiagnostics #Roche 👉 https://lnkd.in/dzsjyfKK

It's great to see momentum with biosimilars continue to impact the US market. Having been talking about these for years and involved in the Pricing & Contracting strategies for the first biosimilars in the US it's interesting to see their impact continue to evolve. No doubt brands must continue to adapt their strategies in access to stay competitive.

On January 31st, Novartis released its 2023 annual report, with global net sales of $45.44 billion, a year-on-year increase of 10%. The growth in sales is mainly due to the sustained strong performance of Entresto (+31% cc), Kesimpta (+99% cc), Kisqali (+75% cc), Pluvicto (+261% cc), and Scamblix (+179% cc). In the fourth quarter, net sales reached $11.423 billion, an increase of 10%, and core operating revenue increased by 13%.

Trending Business-News-Sponsored by Buildbrandonline.com Eli Lilly leaps as weight-loss-drug sales drive earnings and 2024 outlook #business #corporation #businessowner #marketing #smallbusiness #sales #onlinepresence #brand #branding https://lnkd.in/gVAiQQg5

The global Diabetes Drugs Market was worth USD 62.56 billion in 2022 and is anticipated to grow to USD 108.19 billion by 2030 at a CAGR of around 7.22% over 2020-2030. The top 10 best-selling drugs in 2024 were: 𝐖𝐞𝐠𝐨𝐯𝐲 (𝐬𝐞𝐦𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞) 𝐛𝐲 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤 - $5.2 billion in sales 𝐎𝐳𝐞𝐦𝐩𝐢𝐜 (𝐬𝐞𝐦𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞) 𝐛𝐲 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤 - $4.8 billion in sales 𝐒𝐚𝐱𝐞𝐧𝐝𝐚 (𝐥𝐢𝐫𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞) 𝐛𝐲 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤 - $1.9 billion in sales 𝐌𝐨𝐮𝐧𝐣𝐚𝐫𝐨 (𝐭𝐢𝐫𝐳𝐞𝐩𝐚𝐭𝐢𝐝𝐞) 𝐛𝐲 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲 - $1.5 billion in sales 𝐑𝐲𝐛𝐞𝐥𝐬𝐮𝐬 (𝐨𝐫𝐚𝐥 𝐬𝐞𝐦𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞) 𝐛𝐲 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤 - $1.2 billion in sales 𝐂𝐨𝐧𝐭𝐫𝐚𝐯𝐞 𝐛𝐲 𝐂𝐮𝐫𝐫𝐚𝐱 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 - $450 million in sales 𝐐𝐬𝐲𝐦𝐢𝐚 𝐛𝐲 𝐕𝐢𝐯𝐮𝐬 𝐏𝐡𝐚𝐫𝐦𝐚 - $350 million in sales 𝐏𝐥𝐞𝐧𝐢𝐭𝐲 𝐛𝐲 𝐆𝐞𝐥𝐞𝐬𝐢𝐬 - $200 million in sales 𝐒𝐮𝐩𝐫𝐞𝐧𝐳𝐚 𝐛𝐲 𝐏𝐫𝐚𝐬𝐜𝐨 - $150 million in sales 𝐈𝐦𝐜𝐢𝐯𝐫𝐞𝐞 𝐛𝐲 𝐑𝐡𝐲𝐭𝐡𝐦 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 - $100 million in sales #diabetes #glp1 #ozempic #wegovy #mounjaro #rybelsus #semaglutide #tirzepatide #newbusiness #anda #generic #drugs #pharma #weighloss #obesity

✨ 📈 Just last year, Ashton Tweed caught up with Mohamed Ladha, President & General Manager of Recordati Rare Diseases North America, to learn more about the secrets to his leadership style and what brought him to “focus on the few.” 📈 ✨ Just recently, Recordati announced an $825M acquisition of Enjaymo – the first and only therapy specifically approved by the FDA for treating hemolysis in patients with CAD - from Sanofi. You can read the article to learn about... 😊 How best to get to know a new company and new direct reports 🧗 Mohamed’s advice for moving up the career ladder 🧬 Launching multiple products around the world https://lnkd.in/dVCfidjG